(Received for publication, September 18, 1995; and in revised form, November 21, 1995)
From the
Endogenous retinoic acid (RA) has been observed in vertebrate embryos as early as gastrulation, but the mechanism controlling spatiotemporal synthesis of this important regulatory molecule remains unknown. Some members of the alcohol dehydrogenase (ADH) family catalyze retinol oxidation, the rate-limiting step in RA synthesis. Here we have examined mouse embryos for the presence of endogenous RA and expression of ADH genes. RA was not detected in egg cylinder stage embryos but was detected in late primitive streak stage embryos. Detection of class IV ADH mRNA, but not class I or class III, coincided with the onset of RA synthesis, being absent in egg cylinder embryos but present in the posterior mesoderm of late primitive streak embryos. During neurulation, RA and class IV ADH mRNA were colocalized in the craniofacial region, trunk, and forelimb bud. Class IV ADH mRNA was detected in cranial neural crest cells and craniofacial mesenchyme as well as trunk and forelimb bud mesenchyme. The spatiotemporal expression pattern and enzymatic properties of class IV ADH are thus consistent with a crucial function in RA synthesis during embryogenesis. In addition, the finding of endogenous RA and class IV ADH mRNA in the craniofacial region has implications for the mechanism of fetal alcohol syndrome.
Retinoic acid (RA), ()a metabolite of vitamin A
(retinol), is known to regulate differentiation during vertebrate
embryogenesis (Maden, 1994; Hofmann and Eichele, 1994) by acting as a
ligand controlling the activity of the retinoic acid receptor (RAR)
family of transcriptional regulators (Kastner et al., 1994;
Mangelsdorf et al., 1994). Studies on mice carrying RAR null
mutations have shown that RA plays a crucial role in the development of
the craniofacial region (cranial neural crest), skeleton, and numerous
organs (Lohnes et al., 1994; Mendelsohn et al.,
1994). Many of the defects noticed in RAR mutants are also present in
vitamin A-deficient vertebrate embryos (Wilson et al., 1953;
Dersch and Zile, 1993). Information on the presence of endogenous RA
during development is available from a variety of vertebrate embryos.
In avian and amphibian embryos RA has been detected during gastrulation
in Hensen's node and Spemann's organizer, respectively,
(Chen et al., 1992, 1994; Twal et al., 1995) as well
as in the forelimb bud (Thaller and Eichele, 1987; Scadding and Maden,
1994) and floor plate of the neural tube (Wagner et al.,
1990). In mammalian embryos RA has been detected in the retina
(McCaffery et al., 1993), spinal cord (Wagner et al.,
1992; McCaffery and Dräger, 1994; Horton and Maden,
1995), and forelimb bud (Scott et al., 1994; Horton and Maden,
1995). Gastrulation stage mouse embryo tissues are capable of RA
synthesis, occurring preferentially in the node (Hensen's node
equivalent) and primitive streak (Hogan et al., 1992). The
involvement of RA in mouse cranial neural crest development has been
inferred from studies on the teratogenic effects of RA excess
(Morriss-Kay, 1993) as well as RAR mutations (Lohnes et al.,
1994). These findings suggest that synthesis of RA from retinol may be
regulated spatially and temporally in the developing embryo, thus
providing a mechanism to differentially activate the RA receptors.
Retinol, like other alcohol compounds, is converted by a two-step oxidative process to an aldehyde, retinal, and then to a carboxylic acid, RA, with the first reaction representing the rate-limiting step (Kim et al., 1992; Blaner and Olson, 1994). While members of the aldehyde dehydrogenase enzyme family have been implicated as catalyzing the second step of RA synthesis in early mouse embryos (McCaffery et al., 1992, 1993; McCaffery and Dräger, 1994), the physiologically relevant catalyst for the first step, the oxidation of retinol, in early embryonic tissues remains obscure. The enzyme responsible for a retinol dehydrogenase activity purified from the adult mouse epidermis (Connor and Smit, 1987) was found to be identical to a cytosolic medium chain alcohol dehydrogenase (ADH) previously purified from the mouse stomach (Algar et al., 1983), now identified by our laboratory as class IV ADH (Zgombic-Knight et al., 1995). Evidence has also been presented that a microsomal retinol dehydrogenase exists and that the adult rat liver form is a member of the short chain dehydrogenase/reductase family (Chai et al., 1995). The ADH and short chain dehydrogenase/reductase enzyme families are related evolutionarily, sharing a similar coenzyme-binding domain, but differ in that ADH has a greater subunit molecular weight and is zinc-dependent, whereas the other family has a shorter subunit and no metal requirement (Persson et al., 1991). Whereas both the ADH and short-chain dehydrogenase/reductase families are now known to contain retinol dehydrogenases expressed in adult tissues, an embryonic retinol dehydrogenase associated with early RA synthesis has not previously been described.
The ADH family contains the classical liver ADH (now known as class I ADH) responsible for ethanol metabolism in vertebrates, as well as several other classes that preferentially oxidize alcohols other than ethanol (Danielsson et al., 1994). Five classes of enzymes have been identified in the human ADH gene family, but we have shown that the mouse ADH gene family contains only three of these classes, i.e. genes encoding ADH classes I, III, and IV (Zgombic-Knight et al., 1995). In particular, the conserved human and rodent class IV ADHs have been found to have a higher specificity for retinol than other members of the ADH family (Boleda et al., 1993; Yang et al., 1994). We have also demonstrated that mouse class IV ADH is expressed in a wide variety of epithelia, the main retinoid target tissue of adults, further suggesting that retinol oxidation may be a primary function of this enzyme (Zgombic-Knight et al., 1995). In this study we have compared the presence of endogenous RA in mouse embryos with the expression of all three classes of mouse ADH during early embryogenesis and have found that class IV ADH mRNA colocalizes with RA.
Cell stocks were maintained at 37 °C and
5% CO in 0.1% gelatin-coated plates in L15 CO
tissue culture medium with FVM and 1:1:2 supplements containing
antibiotics (Specialty Media, Inc., Lavallette, NJ), 10% fetal calf
serum, and 0.2 mg/ml G418. In our hands the F9-RARE-lacZ cells
were found to be sensitive to subnanomolar concentrations of RA;
-galactosidase activity was detected in control F9-RARE-lacZ cells incubated with as little as 0.1 nM RA added to the
above media, and there was virtually no background detection of
-galactosidase in cells incubated without added RA.
For tissue
explant studies, F9-RARE-lacZ cells were grown in
gelatin-coated 24-well plates in the above media without G418 until
80-90% confluent, at which time embryonic tissues were placed on
top of the monolayer and incubated for 18 h. Whole embryos were
dissected away from the decidua and ectoplacental cone in tissue
culture medium prior to culturing as explants. Following incubation,
the reporter cells were fixed in 1% glutaraldehyde, and
-galactosidase activity was visualized with
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-gal)
as described (Lim and Chae, 1989). This colorimetric assay enabled
detection of RA that had been released from the tissue explant and
diffused to the reporter cells. In many cases the embryonic tissue
remained fixed to the reporter cells, allowing a determination of
differential release of biologically active forms of RA from various
portions of the embryo.
Figure 1:
Histochemical detection of RA release
from mouse embryo tissues incubated on a monolayer of F9-RARE-lacZ reporter cells. The stages indicated refer to the stage of the
embryo at dissection prior to overnight incubation, which resulted in
some additional growth. A, 6.5 dpc embryo attached to the
reporter cell monolayer showing no detectable RA release from either
embryonic (em) or extraembryonic (ex) tissue. B, 7.5 dpc embryo attached to the reporter cells showing
-galactosidase activity (RA release) adjacent to the embryonic (em) but not extraembryonic (ex) tissue. C,
reporter cells indicating RA release from a 7.5 dpc embryo after its
removal from the monolayer. D, 8.5 dpc embryo attached to the
reporter cells showing a large amount of RA release from the trunk and
a smaller amount from the cranial region (arrow) in the
vicinity of the optic eminence (op). E, the same as D except with the embryo removed to more clearly observe the
reporter cells. Notice the RA release from the cranial region (arrow). F, 9.5 dpc embryo (not attached to the
reporter cells) placed next to the site where it was incubated on the
reporter cells. Notice the larger amount of RA release from the trunk
in the prospective forelimb region. Also, note the cranial RA release (arrow) centered in the vicinity of the optic eminence (op), which was much greater than the RA release from either
the midbrain (mb) or hindbrain (hb). G, 9.5
dpc embryonic head (dissected just anterior to the first branchial arch
and incubated with the cut edge down) showing RA release from the left
and right optic eminences (op). H, 9.5 embryonic head
from G removed from the reporter cells and placed on its side
to more clearly observe the RA release from the optic eminences (op) and the absence of RA release from the anterior hindbrain (hb) where the cut was made. I, 9.5 dpc craniofacial
region (dissected away from the midbrain-hindbrain tissue) lying next
to its site of attachment to the reporter cells indicating RA release. J, 9.5 dpc posterior midbrain-anterior hindbrain region lying
next to its attachment site showing no RA release. K, 9.5 dpc
forelimb bud attached to the reporter cells indicating extensive RA
release; the limb was removed at the proximal region and was placed on
top of the reporter cells. L, 10.5 dpc forelimb bud attached
to the reporter cells indicating a small amount of RA release from the
proximal (pr), but not the distal (di) region and
equal RA release along the anterior-posterior axis (shown left to right); the limb was removed at the proximal region,
and at this stage the limb is long enough to place it upon the reporter
cells along its proximodistal axis. Magnifications are as follows:
63 (A-C, K, L),
50 (D-E),
35 (G-J), and
20 (F).
When 8.5 dpc embryos undergoing neurulation were cultured on the RA reporter cells they underwent the characteristic axial rotation sequence (to attain the characteristic fetal position), and almost all embryos (24 out of 25 analyzed) were observed to release large amounts of RA from the trunk region as well as smaller amounts of RA from the ventral cephalic region (Fig. 1, D and E). The cephalic site of RA detection corresponds to the optic eminences, which at this stage contain the optic vesicles as well as surrounding perioptic mesenchyme derived from the cranial neural crest. Thus, in 8.5 dpc embryos a preference for RA release from posterior tissues derived from the primitive streak was observed, but RA was also detected in the cranial region.
Embryos at 9.5 dpc incubated on the RA reporter cells (12 out of 12 examined) also released RA in large amounts from the trunk and smaller amounts from the head. The maximum amount of RA release noted in the trunk was centered in the prospective forelimb bud region, with less RA release in the posterior trunk (Fig. 1F). In the head, maximum RA release was observed in the vicinity of the craniofacial region (optic eminence) with much less RA detected in the posterior hindbrain (Fig. 1F). We also examined RA release from 9.5 dpc head tissue dissected anterior to the first branchial arch and found that RA was localized to the craniofacial region but was absent from the anterior hindbrain (6 out of 6 examined) (Fig. 1, G and H). Upon further dissection we observed that RA was indeed released from craniofacial tissue including the optic eminence (3 out of 3 examined) (Fig. 1I), but not from tissue containing the posterior midbrain-anterior hindbrain (0 out of 3 examined) (Fig. 1J).
RA was also easily detected in dissected 9.5 dpc forelimb bud tissue incubated on the RA reporter cells (18 out of 18 examined); no anterior-posterior difference was noted, and the limb buds were not large enough to determine if a proximal-distal difference existed (Fig. 1K). Some forelimb buds from 10.5 dpc embryos were observed to release small amounts of RA (4 out of 12 examined) and were large enough to determine that RA was released from only from the proximal side near the attachment to the trunk, and equally along the anterior-posterior axis (Fig. 1L).
Figure 2:
Detection of class IV ADH mRNA by
whole-mount in situ hybridization of mouse embryos from
6.5-9.5 dpc. A, 6.5 dpc embryo showing no detection of
mRNA. B, 7.0 dpc embryo showing class IV ADH mRNA in the
posterior region, i.e. the primitive streak (ps). C, 7.5 dpc embryo showing mRNA in the primitive streak (ps). D, 8.0 dpc embryo showing mRNA in the neural
folds (nf) as well as the primitive streak (ps) whose
posterior boundary is marked by the allantois (al). E, shown is a frontal view of an 8.0 dpc embryo indicating
neural fold (nf) mRNA. F, 8.5 dpc embryo showing
class IV ADH mRNA in the neural folds (nf), trunk, and caudal
neuropore (cn). G, 9.0 dpc embryo in the process of
axial rotation showing mRNA in the neural folds (nf) and
caudal neuropore (cn). H, 9.5 dpc embryo showing mRNA
in the trunk, forelimb bud (fb), and craniofacial region
including the frontonasal mass (fn), optic eminence (op), and maxillary (mx) plus mandibular (md) components of the first branchial arch. Notice the lack
of mRNA in the brain lying dorsal to the craniofacial region.
Magnifications are as follows: 63 (A-F) and
50 (G-H).
Figure 3:
Sections of embryos stained for class IV
and class I ADH mRNA by whole-mount in situ hybridization. A, sagittal section of a 7.0 dpc embryo showing class IV ADH
mRNA localized primarily to the primitive streak (ps) mesoderm
extending from approximately the center of the embryo (node) to the
allantois (a) located at the posterior end of the embryo. B, transverse section of an 8.0 dpc embryo through the
anterior neural groove (ng) showing class IV ADH mRNA in the
cranial region. In the neuroepithelium (ne) of the future
forebrain (fb) and hindbrain (hb), notice the mRNA
along the dorsolateral edge nearest to the cranial mesenchyme (cm) corresponding to the cranial neural crest (nc).
The endoderm of the foregut diverticulum (fg) does not contain
class IV ADH mRNA, nor does the midline mesoderm underlying the neural
groove. C, transverse section of an 8.5 dpc embryo through the
cranial region showing class IV ADH mRNA in the cranial neural folds of
the forebrain (fb) and hindbrain (hb) especially in
the perioptic neural crest mesenchyme (pn) surrounding the
optic pit (o) and in the first and second branchial arch
mesenchyme (b1, b2). D, sagittal section of
a 9.5 dpc embryonic head showing class IV ADH mRNA in the cranial
mesenchyme, i.e. perioptic (pn), maxillary (mx), mandibular (md), and second branchial arch (b2) but not the neuroepithelia of the forebrain (fb), midbrain (mb), and hindbrain (hb) nor
the optic vesicle (op), which have near background levels of
detection. E, sagittal section of a 9.5 dpc embryonic trunk
showing greatest class IV ADH mRNA detection in the posterior somites (s) and paraxial mesoderm (pm) relative to the
anterior somites. F, transverse section of a 9.5 dpc embryo
showing class IV ADH mRNA in the proximal (p) mesenchyme of
the forelimb bud (fl). G, Sagittal section and (H) transverse section of a 9.5 dpc embryo indicating class I
ADH mRNA in the mesonephros (m). Magnifications are as
follows: 200 (A-C, H),
100 (F),
63 (D),
50 (E,
G).
During neurulation at 8.0 dpc, class IV ADH mRNA was observed anteriorly in the neural folds as well as posteriorly in the primitive streak (Fig. 2, D and E). Class IV ADH mRNA in the neural folds of 8.0 dpc embryos was localized to the dorsolateral region of the neuroepithelium corresponding to the site of cranial neural crest cell emigration; mRNA was also observed in the cranial mesenchyme, which consists primarily of neural crest cells that have migrated out of the neuroepithelium and undergone an epithelial-mesenchymal transition (Fig. 3B). At 8.5-9.0 dpc, class IV ADH mRNA was detected in the dorsolateral regions of the neural folds and craniofacial region, as well as in the trunk and caudal neuropore (Fig. 2, F and G). Sections at this stage indicated that class IV ADH mRNA was localized primarily to the perioptic neural crest mesenchyme as well as the first and second branchial arches derived from hindbrain neural crest emigration (Fig. 3C).
At 9.5 dpc class IV ADH mRNA in the head was limited to the ventral craniofacial structures (frontonasal mass, perioptic region, mandibular and maxillary components of the first branchial arch, and the second branchial arch) but was absent or low in all regions of the brain (Fig. 2H). Sections of stained embryos indicated that the class IV ADH mRNA signal was greater in the mesenchyme of the frontonasal, perioptic, and branchial arch regions and close to background in the neuroepithelium of all regions of the brain as well as the optic vesicle (Fig. 3D). At 9.5 dpc class IV ADH mRNA was also detected in the posterior trunk and forelimb bud (Fig. 2H). mRNA in the trunk was primarily localized to paraxial mesoderm, particularly in the most posterior portion of the trunk where somites had not yet formed, as well as in the somites posterior to the forelimb bud (Fig. 3E). Class IV ADH mRNA in the forelimb bud was localized primarily to proximal rather than distal mesenchyme, and no anterior-posterior difference was noted (Fig. 3F).
Figure 4:
Detection of class I and class III ADH
mRNA in mouse embryos by whole-mount in situ hybridization.
Class I ADH mRNA was not detected at 6.5 dpc (A), 7.5 dpc (B), or 8.5 dpc (C) but was detected at 9.5 dpc (D) in the mesonephros (m). Class III ADH mRNA was
detected nearly ubiquitously at all stages analyzed, i.e. 6.5 dpc (E), 7.5 dpc (F), 8.5 dpc (G), and 9.5
dpc (H). Magnifications are as follows: 63 (A-C and E-G),
45 (H),
and
35 (D).
The present results show that embryonic RA synthesis is not yet occurring at the egg cylinder stage (6.5 dpc) but that it commences during the primitive streak stage (i.e. at least by 7.5 dpc). Our findings thus suggest that RA first plays a role in embryogenesis during gastrulation, consistent with two earlier studies addressing the spatial and temporal initiation of RA synthesis during gastrulation. First, expression of a lacZ transgene linked to an RA response element is initially detected at 7.5 dpc limited to the primitive streak of mouse embryos (Rossant et al., 1991). Second, it has been demonstrated that cultured posterior tissues (primitive streak and node) of 7.75 dpc mouse embryos are more competent than anterior tissues (headfold) to convert labeled retinol to RA (Hogan et al., 1992). Thus, our bioassay supports the previously held view that mouse embryos begin to synthesize RA from retinol at approximately 7.5 dpc. Since our RA assay depended upon RA diffusion from the embryo to the reporter cells, it was impossible to determine in 7.5 dpc embryos, due to their small size, whether RA was released preferentially from the posterior end containing the primitive streak as suggested by these other studies (Rossant et al., 1991; Hogan et al., 1992). However, our analysis of older embryos (8.5-9.5 dpc) showed that RA release was indeed more concentrated in the trunk relative to the head. Our studies thus confirm these previous findings and provide a more direct assay for the presence of endogenous RA in mouse embryos.
The potential of various ADHs to function as RA synthetic enzymes during embryogenesis was examined by analyzing the spatiotemporal expression of their genes by whole-mount in situ hybridization. Expression of the class IV ADH gene followed the temporal pattern of RA detection, being observed at 7.5 dpc and thereafter but not at 6.5 dpc. Class IV ADH mRNA as well as RA were both observed in the embryonic tissues, but neither was observed in the extraembryonic tissues at 7.5 dpc. The RA reporter cell bioassay indicates that prior to 7.5 dpc there is an undetectable level of biologically active retinoids in mouse embryos, but by 7.5 dpc and thereafter the enzymatic machinery needed to convert retinol to RA has been established. This suggests that mouse class IV ADH, known to function as a retinol dehydrogenase in vitro (Connor and Smit, 1987), is expressed at the correct time to participate in the initiation of RA synthesis during gastrulation and may catalyze the oxidation of retinol to retinal, the first step of RA synthesis.
Class IV ADH gene expression was also detected in 8.5-9.5 dpc embryos. Prior to neural tube closure class IV ADH mRNA was transiently detected along the dorsolateral regions of the anterior neural folds and caudal neuropore. After neural tube closure class IV ADH mRNA was not detected in the neuroepithelium and was instead localized in the craniofacial region, forelimb buds, and posterior trunk. Our bioassay detected RA in most of the tissues expressing class IV ADH mRNA, particularly the craniofacial region, forelimb bud, and trunk (centered at the site of forelimb bud attachment). Thus, these tissues are apparently able to catalyze both steps of RA synthesis, retinol oxidation and retinal oxidation, with class IV ADH a very likely candidate for catalyzing the first step. We did not detect RA in the dorsolateral regions of the anterior neural folds in 8.5 dpc embryos subjected to the bioassay. However, this could be due to a threshold effect, since the class IV ADH expression in this tissue was transient and the neural folds were nearly completely fused after overnight incubation. Such embryos developed in vitro to approximately the 9.0 dpc stage, which, as indicated in our studies, has very little class IV ADH mRNA remaining in the neural folds.
Our bioassay detection of RA in the trunk of 8.5-9.5 dpc embryos, with a maximum in the prospective forelimb region, indicated an anterior skewing relative to the expression pattern of class IV ADH mRNA, which has a maximum just posterior to the prospective forelimb region. The RA indicator mice described above also indicate that the RA maximum in the trunk lies in the vicinity of the prospective forelimb, with less RA in the posterior trunk (Rossant et al., 1991; Balkan et al., 1992). This could indicate that the expression of class IV ADH sets up a field in which retinol is oxidized to retinal but that the synthesis of RA in that field is also dependent upon enzymes that can catalyze the oxidation of retinal to RA.
Class I ADH gene
expression did not commence until 9.5 dpc and was limited to the
mesonephros, a structure that gives rise to portions of the
genitourinary system. Class I ADH functions as both a retinol
dehydrogenase and an ethanol dehydrogenase in vitro (Boleda et al., 1993; Yang et al., 1994), but these results
show that its gene is expressed too late to participate in embryonic RA
synthesis during gastrulation. Despite this, class I ADH may contribute
to the large amount of RA observed in the trunk of 9.5 dpc embryos.
Also, class I ADH mRNA persisted in the mesonephros of 10.5 dpc
embryos, whereas class IV ADH mRNA was absent in the embryo by this
stage. ()Thus, class I ADH may contribute to the RA detected
by others in the trunk of 10.5 dpc mouse embryos (McCaffery and
Dräger, 1994). During late embryonic development
and adulthood class I and class IV ADH mRNAs appear in the adrenal
gland as well as the specialized epithelia of the genitourinary tract,
respiratory tract, digestive tract, and skin, which are known to
require RA for differentiation.
Class III ADH gene expression was already apparent by 6.5 dpc and continued nearly ubiquitously through 9.5 dpc. Expression of the class III ADH gene at the egg cylinder stage, which is prior to our observation of RA, suggests that its function is not to generate RA. In fact, class III ADH has been previously demonstrated to be inactive as a retinol dehydrogenase (Boleda et al., 1993; Yang et al., 1994), and instead has been shown to function as a glutathione-dependent formaldehyde dehydrogenase (Koivusalo et al., 1989). The ubiquitous production of mRNA for class III ADH is consistent with the proposed housekeeping role of this enzyme in removing metabolically generated formaldehyde and is inconsistent with a role in the synthesis of RA, which we have shown is present endogenously in a distinct spatial and temporal pattern.
A novel
finding in our studies was the colocalization of endogenous RA and
class IV ADH expression in the craniofacial tissues known to be
populated primarily by migrating cranial neural crest cells. Vital dye
analysis of mouse embryos has shown that the dorsal neuroepithelia (i.e. dorsolateral regions of the neural folds) in the
forebrain, midbrain, and hindbrain all contribute cranial neural crest
cells, which exit the neuroepithelium and migrate ventrally during
approximately 8.0-9.5 dpc to form the mesenchyme of the
frontonasal mass, perioptic region, first branchial arch (maxillary and
mandibular components), and the remaining branchial arches (Serbedzija et al., 1992; Osumi-Yamashita et al., 1994). A role
for endogenous RA in the development of the craniofacial region is
apparent from studies on mice mutant for both RAR and RAR
,
which have malformations of almost all cranial neural crest mesenchymal
derivatives (Lohnes et al., 1994). Also, a study using a lacZ transgene linked to an RA response element suggested that
RA exists in the perioptic neural crest mesenchyme (Rossant et
al., 1991; Balkan et al., 1992). Using a different method
of detection, our studies indicate that endogenous RA does in fact
exist in the craniofacial region from 9.0-9.5 dpc but is absent
from the brain. In addition, we have found that class IV ADH expression
at these stages occurs in the cranial neural crest and craniofacial
region but not the brain. Our data thus provide evidence that after the
initiation of RA synthesis in posterior tissues of primitive streak
embryos, class IV ADH then participates in the initiation of RA
synthesis anteriorly in the cranial neural crest. By 9.5 dpc, class IV
ADH expression and significant RA levels were both associated with the
craniofacial mesenchyme but not brain or neural tube tissue, suggesting
that class IV ADH catalyzes RA synthesis in the cranial neural crest
mesenchyme following the completion of neural crest cell migration from
the neuroepithelium.
These findings have implications for the mechanism of ethanol-induced birth defects during human embryogenesis. Fetal alcohol syndrome is characterized by craniofacial defects of the eyes, upper lip, and jaw (short palpebral fissures, hypoplastic philtrum, maxillary hypoplasia, cleft palate, and micrognathia) arising from improper development of the cranial neural crest (Jones and Smith, 1973; Clarren and Smith, 1978). Very similar defects have also been observed in mouse embryos treated with ethanol during gastrulation (Sulik et al., 1981; Webster et al., 1983). Ethanol is a much poorer substrate for class IV ADH than retinol, but at very high doses ethanol has been shown to compete with retinol for access to the enzyme, leading to inhibition of retinol oxidation (Juliàet al., 1986; Duester, 1995). We have proposed that the negative effects of excess ethanol consumption during pregnancy, as manifested by fetal alcohol syndrome, may be caused by an inhibition of ADH-catalyzed RA synthesis in the cranial neural crest leading to a failure of RAR function needed for normal development (Duester, 1991; Duester, 1994). In order for this hypothesis to be correct, an ADH capable of retinol oxidation must be expressed in the correct spatiotemporal pattern. Our observation of class IV ADH gene expression and endogenous RA in craniofacial tissues thus lends credence to this model.
A concentration gradient of endogenous RA has been proposed to play a role in anterior-posterior patterning of the embryo by differentially regulating members of the hox gene family (Simeone et al., 1990). This has been supported by studies indicating a posterior preference for RA accumulation in embryos (Rossant et al., 1991; Balkan et al., 1992; Hogan et al., 1992; Chen et al., 1992; Chen et al., 1994; Wagner et al., 1992; McCaffery and Dräger, 1994; Horton and Maden, 1995). Our RA bioassay results support the existence of a posterior preference for RA accumulation in 8.5-9.5 dpc mouse embryos with the high point located in that region of the trunk containing the prospective forelimb buds and the low point located in the posterior midbrain-anterior hindbrain region. Class IV ADH expression followed this pattern as well, suggesting that this enzyme participates in establishing an anterior-posterior RA gradient along the embryo with the high end located in the trunk.
RA has also been found to exist in an anterior-posterior gradient in the chick and amphibian forelimb buds (Thaller and Eichele, 1987; Scadding and Maden, 1994), but no convincing evidence for such a gradient has been found in the mouse forelimb bud (Rossant et al., 1991; Scott et al., 1994). Our data also indicates that RA in the mouse forelimb bud is not localized in an anterior-posterior gradient. On the contrary, our analysis of 10.5 dpc mouse forelimb buds suggests that there may exist a proximal-distal gradient (high proximally). This finding is consistent with a study indicating that expression of a lacZ transgene linked to an RA response element is observed only at the proximal base of the forelimb bud where it attaches to the trunk (Rossant et al., 1991). Importantly, we have identified that class IV ADH expression is also preferentially localized in the proximal rather than distal forelimb bud mesenchyme, thus indicating that it may participate in RA synthesis in this location.
Neither class IV ADH nor class I ADH were expressed in the floor plate of the neural tube or the embryonic retina, suggesting that these retinol dehydrogenases do not participate in the synthesis of RA previously detected in those tissues (Wagner et al., 1990, 1992; McCaffery et al., 1993; McCaffery and Dräger, 1994). Since an aldehyde dehydrogenase that can oxidize retinal to RA has been identified in these tissues (McCaffery et al., 1993; McCaffery and Dräger, 1994), further studies are needed to identify a retinol dehydrogenase responsible for the production of retinal.
The link we have found between class IV ADH gene expression
and endogenous RA in mouse embryos has implications for our
understanding of the mechanism of RA synthesis. Liver class I ADH was
early established as a cytosolic NAD-linked retinol dehydrogenase that
could catalyze the in vitro oxidation of retinol for RA
synthesis (Bliss, 1951; Zachman and Olson, 1961). However, the role of
this enzyme in vivo was questioned by the discovery of a class
I ADH mutant deer mouse that could produce sufficient RA for survival
(Posch et al., 1989). Subsequently, a liver microsomal
NADP-linked retinol dehydrogenase (short chain dehydrogenase/reductase)
that in vitro functions best with retinol bound to cellular
retinol binding protein type I was proposed to be the physiological
catalyst in the oxidation of retinol for RA synthesis (Posch et
al., 1991; Chai et al., 1995). However, since this enzyme
uses NADP(H) as its coenzyme it may preferentially bind NADPH (due to
the low ratio of NADP to NADPH) and function as a retinal reductase to
convert retinal to retinol. Cells normally maintain their NADP/NADPH
ratio near 0.01, which favors metabolite reduction for enzymes using
this coenzyme, while keeping their NAD/NADH ratio near 1000, which
favors metabolite oxidation for enzymes using this coenzyme (Veech et al., 1969). These coenzyme concentrations would be expected in vivo to direct the microsomal retinol dehydrogenase to
function in the reductive direction and ADH retinol dehydrogenases in
the oxidative direction. The reductive reaction is known to occur in
the intestine where the breakdown of -carotene (the ultimate
source of all retinoids) produces retinal, which is reduced to retinol
by a microsomal retinal reductase activity that functions best with
retinal bound to cellular retinol binding protein type II (Kakkad and
Ong, 1988). Conversion of
-carotene to retinal and retinol is also
known to occur to a lesser extent in the liver and other organs (Olson,
1989). Thus, there exists a biochemical argument suggesting that the
liver microsomal retinol dehydrogenase may not catalyze retinol
oxidation in vivo but rather retinal reduction. The discovery
that class IV ADH, originally isolated in the epidermis and stomach
mucosa, functions as a NAD-linked retinol dehydrogenase (Connor and
Smit, 1987; Boleda et al., 1993; Yang et al., 1994)
opens the possibility that this form of ADH may be a physiological
catalyst for RA synthesis. Class IV ADH is present in all mammals so
far analyzed including the wild type and mutant deer mouse (Zheng et al., 1993; Zgombic-Knight et al., 1995). Thus, the
absence of class I ADH in the mutant deer mouse may be compensated for
by the presence of class IV ADH. We have now shown that the class IV
ADH gene is expressed prior to the class I ADH gene during the onset of
embryonic RA synthesis, suggesting that it plays a more crucial role in
RA synthesis. Thus, our studies indicate that future investigations of
the RA synthetic mechanism should put particular emphasis upon the role
of class IV ADH. It is clear that we do not yet know the relative in vivo contributions of ADHs, microsomal retinol
dehydrogenases, and cellular retinol binding proteins for RA synthesis
during embryogenesis or subsequent maintenance of adult functions.
Mutational studies of all these components may be necessary to
determine what roles they play in RA synthesis or other aspects of
retinoid metabolism.